Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Bayer Schering/Johnson & Johnson's Rivaroxaban will overtake GlaxoSmithKline's Arixtra as the clinical gold standard for the prophylaxis of venous thromboembolism by 2010. According to the new report entitled Emerging Oral Anticoagulants Will Challenge Heparin Dominance: A Venous Thromboembolism Study, rivaroxaban will feature improvements in safety and delivery over Arixtra that will make it the gold standard for treatment.
Currently available anticoagulants, including heparin, have several shortcomings such as a narrow therapeutic window that requires close monitoring, and an unpredictable dose response including serious side effects such as hemorrhaging and heparin-induced thrombocytopenia. Rivaroxaban is orally administered, has a decreased need for monitoring, and its risk for thrombocytopenia is far less than that posed by Arixtra. Also, it scores more favorably than the emerging competitor Boehringer Ingelheim's Rendix because of its once-daily dosing.
"Rivaroxaban will feature improvements in safety and delivery over Arixtra. These areas are important enough to prescribers to make rivaroxaban the gold standard in our model" said Muneer Ahmad, Ph.D., analyst at Decision Resources. "Eli Lily's LY-517717 is predicted to be launched in 2013 and the product appears to have efficacy comparable to benchmark therapies and a safety that is superior to that of rivaroxaban with respect to major and minor bleeding events. LY-517717's once-daily dosing is also a key differentiator in a potentially crowded market."
About Emerging Oral Anticoagulants Will Challenge Heparin Dominance: A Venous Thromboembolism Study
Emerging Oral Anticoagulants Will Challenge Heparin Dominance: A Venous Thromboembolism Study covers the current and future state of the venous thromboembolism drug market. The report includes the following:
-- More than 3,000 physician responses that define drug attributes that drive prescription now and in the future. -- Clinical end point tradeoffs that are most influential to physicians. -- Areas of unmet need with highest potential. -- Benchmark trial results for specific drug opportunities. -- Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. -- Promotion: DTC spend, detailing intensity. -- Reimbursement: formulary tier, prior approval restriction, quantity limits. -- Labeling: black box warnings, approved patient segments, contraindications. -- Competition: order of entry, pricing, generic entry, pipeline sales forecast. -- Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identifies the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or firstname.lastname@example.org
Web site: http://www.decisionresources.com/